<DOC>
	<DOCNO>NCT01949129</DOCNO>
	<brief_summary>The ALL SCTped 2012 FORUM multinational , multi-centre , randomize , control , prospective seamless phase II/III study therapy therapy optimisation child adolescents ALL CR , indication HSCT ( hematopoetic stem cell transplantation ) myeloablative condition regimen . The stratification randomisation patient first follow remission accord individual transplantation modality rest upon indication allogeneic HSCT AND availability suitable donor within individual transplantation group . Main objectives - Objective 1 : Randomisation TBI vs non-TBI condition regimen patient HLA matched-sibling donor unrelated HLA match donor . We aim show non-total body irradiation ( TBI ) contain conditioning ( Flu/Thio/ivBu Flu/Thio/Treo ) result non-inferior survival compare conditioning TBI/Etoposide child older 4 year HSCT Human leucocyte antigen ( HLA ) identical sibling donor ( MSD ) HLA match donor ( MD ) . - Objective 2 : Stratification patient HLA mismatch donor accord stem cell source . We aim explore event free survival ( EFS ) HSCT HLA mismatch donor use mismatch unrelated donor ( MMD ) , mismatch cord blood HLA haplo-identical family member non TBI-conditioning regimen .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplantation Children Adolescents With Acute Lymphoblastic Leukaemia</brief_title>
	<detailed_description>Acute late side effect TBI combination chemotherapeutic manifold grow organism include severe organ dysfunction/failure due toxicity . Although transplant associate mortality reduce HSCT last decade due good HLA matching , infection prevention control , burden late complication still matter concern.Growth retardation , hormonal dysfunction , sterility risk secondary cancer late consequence TBI children.However , far prospective study demonstrate similar outcome paediatric ALL use chemo-conditioning regimen HSCT.The reason manifold : minority child ALL qualify allogeneic HSCT patient cure modern chemotherapy approach alone . Those dismal prognosis treat HSCT centre care patient different disease . Therefore nearly impossible answer complex outcome question single centre even single country . International cooperation essential allow prospective randomize investigation within comparable patient cohort . This study aim explore efficacy efficiency two different chemo-conditioning regimen ( Flu/Thio Treo ivBu ) comparison standard condition regimen ( TBI/VP16 ) . All patient indication HSCT , age &gt; 4 year match donor ( MD ) match sibling donor ( MSD ) undergo randomisation two conditioning . The decision irradiation free conditioning Flu/Thio/Treo Flu/Thio/ivBu stratify country . Patients age &lt; 4 year receive automatically irradiation free conditioning . Patients mismatch donor stratify accord donor 's stem cell source ( cordblood , haploidentical tx bone marrow/peripheral blood stem cell ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients ALL ( except patient BALL ) fulfil follow criterion : age time screen less 18 year indication allogeneic HSCT complete remission ( CR ) HSCT write consent parent ( legal guardian ) , necessary , minor patient via `` Informed Consent Form '' pregnancy secondary malignancy previous HSCT HSCT perform study participate centre Patients fulfil inclusion criterion Non HodgkinLymphoma ALL extramedullary involvement indication TBI CNS involvement timepoint screen Trisomy 21 The whole protocol essential part decline either patient himself/herself respective legal guardian No consent give save propagation anonymous medical data study reason Severe concomitant disease allow treatment accord protocol investigator 's discretion ( e.g . malformation syndrome , cardiac malformation , metabolic disorder ) Karnofsky / Lansky score &lt; 50 % Subjects unwilling unable comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stem cell transplantation</keyword>
	<keyword>child adolescent</keyword>
	<keyword>high risk acute lymphoblastic leukaemia</keyword>
</DOC>